Is This BSX Stock Pullback Worth The Patience?
Boston Scientific (BSX) trades at about $43, roughly 17% below the recent high it set on 19th Aug, 2026. Its own history with sharp drops is encouraging. That history does not cover a cyberattack it says is likely to hit its 2026 results, and the stock is down about 60% over the past twelve months. Start with the history.
Does Boston Scientific Pay Back Its Dip Buyers?
Since 2010, Boston Scientific has fallen 20% or more inside 30 trading days six times. Four are old enough to have a full year behind them, and all four ended higher twelve months later, at a median gain of 18%. The two most recent are too young to have a one-year result.
Collecting that gain was uncomfortable. Among those four, the median buyer sat through a further 17% decline first, and the worst further fall in the whole record was 44%. The median peak gain of 30% took about 226 days to arrive, close to seven and a half months. Waiting, not timing, is what that history rewards.
The record behind those medians is below.
BSX had 6 events since 1/1/2010 where the dip threshold of -20% within 30 days was triggered
- 30% median peak return within 1 year of dip event
- 226 days is the median time to peak return after a dip event
- -17% median max drawdown within 1 year of dip event
| Period | Past Median Return |
|---|---|
| 1M | 1.0% |
| 3M | -7.0% |
| 6M | -1.9% |
| 12M | 17.9% |
| 30 Day Dip | BSX Subsequent Performance | |||||||
|---|---|---|---|---|---|---|---|---|
| Date | BSX | SPY | 1Y | Peak Return |
Max Drop |
# Days to Peak |
||
| Median | 18% | 30% | -17% | 226 | ||||
| 5082026 | -23% | 14% | -21% | 14 | ||||
| 2042026 | -21% | 1% | -44% | 1 | ||||
| 11232020 | -21% | 1% | 21% | 38% | -1% | 252 | ||
| 3092020 | -21% | -17% | 16% | 24% | -24% | 177 | ||
| 6042010 | -20% | -12% | 20% | 37% | -11% | 200 | ||
| 3152010 | -21% | 8% | 7% | 15% | -25% | 281 | ||
[2] Analysis for period from 1/1/2010 to 9/10/2026
Would You Be Waiting On A Growing Business?
Yes. Revenue grew 13.5% over the trailing twelve months, to $21.0 billion, down from a 16.2% average over the past three years. Its trailing operating cash flow margin is 21.6%, so the business still funds itself. It clears every basic quality check.
The trouble sits in the outlook. In late July management cut full-year 2026 organic revenue growth guidance to 5% to 6%, and said 2027 brings only limited adjusted earnings growth before a recovery in 2028.
Two franchises did it. WATCHMAN, its heart implant for patients who cannot or should not take blood thinners, met slowing US demand as new clinical evidence shifted referral patterns. In Electrophysiology, home to its FARAPULSE platform, competitors took US share faster than management expected. The other 75% of revenue still grows about 6%.
| Quality Metrics | Value | Quality Check |
|---|---|---|
| Revenue Growth (LTM) | 13.5% | Pass |
| Revenue Growth (3-Yr Avg) | 16.2% | Pass |
| Operating Cash Flow Margin (LTM) | 21.6% | Pass |
| Leverage (see below) | – | Pass |
| => Interest Coverage Ratio | 11.6 | |
| => Cash To Interest Expense Ratio | 1.5 |
Is The Guidance Cut What This Fall Is About?
Only partly. The guidance cut reset expectations and capped upside in late July, but the actual slide didn’t begin until 19th Aug, 2026—deepening sharply when a second headwind struck. In late August, the company disclosed a cybersecurity incident that disrupted global operations and customer shipments. In early September it said that disruption is likely to have a material impact on its third-quarter and full-year 2026 results.
This 17% pullback is not one of the six 20% falls the dip record is built on, and the cyberattack did not exist when management set that guidance. The price argues the other way: about 19 times earnings, against roughly 23 for the S&P 500. We have looked at how much upside its growth could deliver. The test comes with the earnings report expected around 28th Oct, 2026, and the line to watch is what the manufacturing and shipping disruption took out of revenue.
So Do You Buy Boston Scientific Down Here?
Only if you can wait, and only if a further fall would not change your mind. Nothing before the October report will settle that for you, and sitting through months of it is harder than deciding to buy.
Two things make the call smaller. One is our Buy The Dip screen, which sets every recent decline beside how that size of drop has played out before.
The other is to stop deciding one stock at a time. That is the thinking behind the Trefis High Quality Portfolio, where quality businesses are sized and re-balanced by rule. That portfolio has a track record of outpacing the three major indices.